JP5757885B2 - Ｐｃｒ用の試薬および方法 - Google Patents
Ｐｃｒ用の試薬および方法 Download PDFInfo
- Publication number
- JP5757885B2 JP5757885B2 JP2011554206A JP2011554206A JP5757885B2 JP 5757885 B2 JP5757885 B2 JP 5757885B2 JP 2011554206 A JP2011554206 A JP 2011554206A JP 2011554206 A JP2011554206 A JP 2011554206A JP 5757885 B2 JP5757885 B2 JP 5757885B2
- Authority
- JP
- Japan
- Prior art keywords
- additive
- primer
- amplification
- target
- stranded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 38
- 239000003153 chemical reaction reagent Substances 0.000 title description 34
- 239000000654 additive Substances 0.000 claims description 661
- 230000000996 additive effect Effects 0.000 claims description 511
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 335
- 230000003321 amplification Effects 0.000 claims description 334
- 238000006243 chemical reaction Methods 0.000 claims description 242
- 239000000523 sample Substances 0.000 claims description 204
- 108091034117 Oligonucleotide Proteins 0.000 claims description 146
- 239000011541 reaction mixture Substances 0.000 claims description 146
- 230000000295 complement effect Effects 0.000 claims description 103
- 239000002773 nucleotide Substances 0.000 claims description 103
- 125000003729 nucleotide group Chemical group 0.000 claims description 102
- 238000000137 annealing Methods 0.000 claims description 101
- 239000000203 mixture Substances 0.000 claims description 88
- 230000000694 effects Effects 0.000 claims description 80
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 75
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 75
- 230000001419 dependent effect Effects 0.000 claims description 38
- 108010010677 Phosphodiesterase I Proteins 0.000 claims description 33
- 230000001965 increasing effect Effects 0.000 claims description 29
- 230000005764 inhibitory process Effects 0.000 claims description 29
- 230000002829 reductive effect Effects 0.000 claims description 25
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims description 19
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims description 19
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims description 19
- 230000004544 DNA amplification Effects 0.000 claims description 10
- 102100034343 Integrase Human genes 0.000 claims description 10
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 10
- 230000004048 modification Effects 0.000 claims description 10
- 238000012986 modification Methods 0.000 claims description 10
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 claims description 3
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000013615 primer Substances 0.000 description 467
- 239000000047 product Substances 0.000 description 192
- 238000002844 melting Methods 0.000 description 128
- 230000008018 melting Effects 0.000 description 123
- 238000003556 assay Methods 0.000 description 104
- 238000012408 PCR amplification Methods 0.000 description 94
- 108020004414 DNA Proteins 0.000 description 81
- 238000003752 polymerase chain reaction Methods 0.000 description 70
- 239000003607 modifier Substances 0.000 description 65
- 238000001514 detection method Methods 0.000 description 60
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 58
- 230000006870 function Effects 0.000 description 55
- 108010006785 Taq Polymerase Proteins 0.000 description 53
- 238000011534 incubation Methods 0.000 description 38
- 230000002441 reversible effect Effects 0.000 description 32
- 108091093088 Amplicon Proteins 0.000 description 27
- 238000002944 PCR assay Methods 0.000 description 25
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 24
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 24
- 102000053602 DNA Human genes 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 22
- 238000009396 hybridization Methods 0.000 description 20
- 239000000872 buffer Substances 0.000 description 18
- 230000001629 suppression Effects 0.000 description 18
- 150000007523 nucleic acids Chemical class 0.000 description 17
- 102000039446 nucleic acids Human genes 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 238000012163 sequencing technique Methods 0.000 description 16
- 238000003776 cleavage reaction Methods 0.000 description 14
- 230000007017 scission Effects 0.000 description 14
- 239000002987 primer (paints) Substances 0.000 description 13
- 238000005382 thermal cycling Methods 0.000 description 13
- 108700028369 Alleles Proteins 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 229910052697 platinum Inorganic materials 0.000 description 12
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 230000037452 priming Effects 0.000 description 11
- 230000007423 decrease Effects 0.000 description 10
- 239000000539 dimer Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 125000003367 polycyclic group Chemical group 0.000 description 10
- 108060002716 Exonuclease Proteins 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 102000013165 exonuclease Human genes 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 238000010839 reverse transcription Methods 0.000 description 9
- 230000003111 delayed effect Effects 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000011880 melting curve analysis Methods 0.000 description 8
- 229920002521 macromolecule Polymers 0.000 description 7
- 230000002438 mitochondrial effect Effects 0.000 description 7
- 108020004682 Single-Stranded DNA Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- -1 bicyclic aromatic coumarins Chemical class 0.000 description 6
- 235000001671 coumarin Nutrition 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000001917 fluorescence detection Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 5
- 101710163270 Nuclease Proteins 0.000 description 5
- 238000007846 asymmetric PCR Methods 0.000 description 5
- 229960000956 coumarin Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000011901 isothermal amplification Methods 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000007403 mPCR Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 238000011897 real-time detection Methods 0.000 description 4
- 108091023037 Aptamer Proteins 0.000 description 3
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 3
- 108020005196 Mitochondrial DNA Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000003366 endpoint assay Methods 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000012933 kinetic analysis Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000010223 real-time analysis Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003375 selectivity assay Methods 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101100020619 Arabidopsis thaliana LATE gene Proteins 0.000 description 1
- 108010075028 Cytochromes b Proteins 0.000 description 1
- 239000009261 D 400 Substances 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 102000004214 DNA polymerase A Human genes 0.000 description 1
- 108090000725 DNA polymerase A Proteins 0.000 description 1
- 229940123014 DNA polymerase inhibitor Drugs 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 description 1
- 102100036243 HLA class II histocompatibility antigen, DQ alpha 1 chain Human genes 0.000 description 1
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000582786 Monoplex Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- MTVVRWVOXZSVBW-UHFFFAOYSA-M QSY21 succinimidyl ester Chemical compound [Cl-].C1CN(S(=O)(=O)C=2C(=CC=CC=2)C2=C3C=CC(C=C3OC3=CC(=CC=C32)N2CC3=CC=CC=C3C2)=[N+]2CC3=CC=CC=C3C2)CCC1C(=O)ON1C(=O)CCC1=O MTVVRWVOXZSVBW-UHFFFAOYSA-M 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940095100 fulvic acid Drugs 0.000 description 1
- 239000002509 fulvic acid Substances 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- NVLRFXKSQQPKAD-UHFFFAOYSA-N tricarbon Chemical compound [C]=C=[C] NVLRFXKSQQPKAD-UHFFFAOYSA-N 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20256509P | 2009-03-12 | 2009-03-12 | |
| US61/202,565 | 2009-03-12 | ||
| PCT/US2010/027011 WO2010105074A1 (en) | 2009-03-12 | 2010-03-11 | Reagents and methods for pcr |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012520080A JP2012520080A (ja) | 2012-09-06 |
| JP2012520080A5 JP2012520080A5 (OSRAM) | 2013-05-02 |
| JP5757885B2 true JP5757885B2 (ja) | 2015-08-05 |
Family
ID=42244601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011554206A Expired - Fee Related JP5757885B2 (ja) | 2009-03-12 | 2010-03-11 | Ｐｃｒ用の試薬および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9034605B2 (OSRAM) |
| EP (2) | EP2406394B1 (OSRAM) |
| JP (1) | JP5757885B2 (OSRAM) |
| CN (1) | CN102421918B (OSRAM) |
| AU (1) | AU2010224100B2 (OSRAM) |
| CA (1) | CA2755207A1 (OSRAM) |
| WO (1) | WO2010105074A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008105814A2 (en) | 2006-08-22 | 2008-09-04 | Los Alamos National Security, Llc | Miniturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids |
| US8980561B1 (en) | 2006-08-22 | 2015-03-17 | Los Alamos National Security, Llc. | Nucleic acid detection system and method for detecting influenza |
| EP2279403B1 (en) | 2008-05-05 | 2016-03-16 | Los Alamos National Security, LLC | Highly simplified lateral flow-based nucleic acid sample preparation and passive fluid flow control |
| EP2406394B1 (en) | 2009-03-12 | 2014-01-08 | Brandeis University | Reagents and methods for pcr |
| US9169514B2 (en) | 2010-12-03 | 2015-10-27 | Brandeis University | Detecting nucleic acid variations within populations of genomes |
| ES2583135T3 (es) | 2011-04-20 | 2016-09-19 | Mesa Biotech, Inc. | Dispositivo integrado para la detección e identificación de ácidos nucleicos |
| JP2015508655A (ja) | 2012-02-14 | 2015-03-23 | コーネル ユニバーシティー | 組み合わせたヌクレアーゼ反応、連結反応、およびポリメラーゼ反応を用いて核酸配列、発現、またはコピー変化を相対的に定量するための方法 |
| EP2948564B1 (en) * | 2013-01-23 | 2019-04-10 | Brandeis University | Reagents for improving pcr accuracy |
| KR102126031B1 (ko) * | 2013-07-23 | 2020-07-08 | 삼성전자주식회사 | 유전적 변이를 함유하는 핵산 검출 방법 |
| CN105378160B (zh) * | 2013-08-12 | 2018-04-17 | 伯乐生命医学产品有限公司 | 具有碱基配对的寡聚体的扩增报告子 |
| US20160222434A1 (en) * | 2013-09-13 | 2016-08-04 | Brandeis University | Modified Polymerase Compositions, Methods and Kits |
| CA2971200A1 (en) | 2014-12-19 | 2016-06-23 | Brandeis University | Mispriming prevention reagents |
| WO2016172724A1 (en) | 2015-04-24 | 2016-10-27 | Mesa Biotech, Inc. | Fluidic test cassette |
| JP6847496B2 (ja) * | 2015-08-06 | 2021-03-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 単一プローブプライマー伸長による標的濃縮 |
| CN108431223A (zh) | 2016-01-08 | 2018-08-21 | 生物辐射实验室股份有限公司 | 每液滴分辨率下的多个珠 |
| CN109601008B (zh) * | 2016-04-01 | 2023-02-28 | 克罗玛科德公司 | 用于工程化信号产生的竞争性探针 |
| CN107541508A (zh) * | 2016-06-24 | 2018-01-05 | 广州康昕瑞基因健康科技有限公司 | 模板‑引物核酸分子、聚合酶活性测定方法及试剂盒 |
| CN108774639B (zh) * | 2018-05-31 | 2023-05-30 | 澳門帝傑數碼基因有限公司 | 一种定向聚合的荧光探针pcr |
| WO2020010124A2 (en) * | 2018-07-02 | 2020-01-09 | Swift Biosciences, Inc. | Temperature controlled dna polymerase inhibitors |
| US20220307066A1 (en) * | 2019-06-14 | 2022-09-29 | University Of Washington | An enzymatic assay to measure long-term adherence to pre exposure prophylaxis and antiretroviral therapy |
| CN114341150B (zh) * | 2019-06-25 | 2025-01-14 | 生物辐射实验室股份有限公司 | 用于增强逆转录酶活性和/或减少逆转录酶抑制的组合物和方法 |
| WO2021168384A1 (en) * | 2020-02-21 | 2021-08-26 | Mission Bio, Inc. | Enhanced detection of target nucleic acids by removal of dna-rna cross contamination |
| JP7209980B2 (ja) * | 2020-12-11 | 2023-01-23 | 東洋紡株式会社 | Ｄｎａポリメラーゼの５’→３’エキソヌクレアーゼ活性ドメインに特異的に結合する抗体 |
| CN115747328A (zh) * | 2022-08-19 | 2023-03-07 | 福建师范大学 | 一种提高单链dna产量和改善产物比例的方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US5994056A (en) | 1991-05-02 | 1999-11-30 | Roche Molecular Systems, Inc. | Homogeneous methods for nucleic acid amplification and detection |
| US5338671A (en) | 1992-10-07 | 1994-08-16 | Eastman Kodak Company | DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody |
| US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
| US20050242506A1 (en) | 1994-07-22 | 2005-11-03 | Shuffle Master, Inc. | Poker game variation with variable size wagers and play against a pay table |
| ATE494394T1 (de) | 1995-06-07 | 2011-01-15 | Gilead Sciences Inc | Nukleinsäureliganden, die an dna-polymerasen binden und diese inhibieren |
| US5773258A (en) | 1995-08-25 | 1998-06-30 | Roche Molecular Systems, Inc. | Nucleic acid amplification using a reversibly inactivated thermostable enzyme |
| CA2252048C (en) | 1996-04-12 | 2008-03-11 | The Public Health Research Institute Of The City Of New York, Inc. | Detection probes, kits and assays |
| US6277607B1 (en) | 1999-05-24 | 2001-08-21 | Sanjay Tyagi | High specificity primers, amplification methods and kits |
| US7198897B2 (en) | 2001-12-19 | 2007-04-03 | Brandeis University | Late-PCR |
| CA2521127C (en) * | 2003-04-01 | 2014-05-27 | Eragen Biosciences, Inc. | Polymerase inhibitor and method of using same |
| JP2007522818A (ja) * | 2004-02-18 | 2007-08-16 | クロモセル コーポレイション | シグナリングプローブを使用する方法および材料 |
| NZ554701A (en) * | 2004-10-18 | 2010-03-26 | Univ Brandeis | Reagents and methods for improving reproducibility and reducing mispriming in PCR amplification |
| RU2460804C2 (ru) * | 2004-10-18 | 2012-09-10 | Брандейс Юнивесити | Способ гомогенной детекции по меньшей мере одного продукта одноцепочечной амплификации |
| CA2614444C (en) * | 2005-07-07 | 2015-12-08 | Quanta Biosciences, Inc. | Compositions and methods for increasing amplification efficiency |
| EP1911852B1 (en) * | 2006-10-12 | 2009-07-29 | Bio-Rad Pasteur | Double-stranded probes for the fluorescent detection of nucleic acids |
| EA200900782A1 (ru) * | 2006-12-14 | 2009-12-30 | Новартис Аг | Композиции и способы, предназначенные для лечения мышечных и сердечно-сосудистых нарушений |
| EP2406394B1 (en) | 2009-03-12 | 2014-01-08 | Brandeis University | Reagents and methods for pcr |
-
2010
- 2010-03-11 EP EP10708682.9A patent/EP2406394B1/en not_active Not-in-force
- 2010-03-11 WO PCT/US2010/027011 patent/WO2010105074A1/en not_active Ceased
- 2010-03-11 US US13/256,038 patent/US9034605B2/en active Active
- 2010-03-11 EP EP13195156.8A patent/EP2703501A1/en not_active Withdrawn
- 2010-03-11 AU AU2010224100A patent/AU2010224100B2/en not_active Ceased
- 2010-03-11 CN CN201080020170.6A patent/CN102421918B/zh not_active Expired - Fee Related
- 2010-03-11 CA CA2755207A patent/CA2755207A1/en not_active Abandoned
- 2010-03-11 JP JP2011554206A patent/JP5757885B2/ja not_active Expired - Fee Related
-
2015
- 2015-05-18 US US14/715,299 patent/US9758813B2/en active Active
-
2017
- 2017-09-08 US US15/698,992 patent/US20180002739A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20120088275A1 (en) | 2012-04-12 |
| EP2406394A1 (en) | 2012-01-18 |
| WO2010105074A1 (en) | 2010-09-16 |
| AU2010224100A1 (en) | 2011-10-27 |
| CN102421918A (zh) | 2012-04-18 |
| US9034605B2 (en) | 2015-05-19 |
| CA2755207A1 (en) | 2010-09-16 |
| JP2012520080A (ja) | 2012-09-06 |
| EP2406394B1 (en) | 2014-01-08 |
| US9758813B2 (en) | 2017-09-12 |
| CN102421918B (zh) | 2016-01-20 |
| EP2703501A1 (en) | 2014-03-05 |
| US20180002739A1 (en) | 2018-01-04 |
| AU2010224100B2 (en) | 2015-10-22 |
| US20150322503A1 (en) | 2015-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5757885B2 (ja) | Ｐｃｒ用の試薬および方法 | |
| US9169514B2 (en) | Detecting nucleic acid variations within populations of genomes | |
| CN101076608B (zh) | 在pcr扩增中提高再现性和降低引物错导的试剂和方法 | |
| US20200032310A1 (en) | Mispriming prevention reagents | |
| Liu et al. | Invading stacking primer: A trigger for high-efficiency isothermal amplification reaction with superior selectivity for detecting microRNA variants | |
| EP2841598B1 (en) | Method for competitive allele-specific cdna synthesis and differential amplification of the cdna products | |
| AU2017385830A1 (en) | Method for reducing primer dimer formation and increasing amplification efficiency | |
| JP2021514637A (ja) | 特異性を改善した核酸を増幅する方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130311 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130311 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140805 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141104 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150205 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150512 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150602 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5757885 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |